title: The biology and therapeutic implications of HDACs in the heart.
abstract: The heart responds to stresses such as chronic hypertension and myocardial infarction by undergoing a remodeling process that is associated with myocyte hypertrophy, myocyte death, inflammation and fibrosis, often resulting in impaired cardiac function and heart failure. Recent studies have revealed key roles for histone deacetylases (HDACs) as both positive and negative regulators of pathological cardiac remodeling, and small molecule HDAC inhibitors have demonstrated efficacy in animal models of heart failure. This chapter reviews the functions of individual HDAC isoforms in the heart and highlights issues that need to be addressed to enable development of novel HDAC-directed therapies for cardiovascular indications.
authors: Department of Medicine, Division of Cardiology, University of Colorado Denver, Aurora, CO 80045-0508, USA. timothy.mckinsey@ucdenver.edu
authors: Timothy A
authors: TA
authors: McKinsey
mesh_terms: D000107:Acetylation; D000818:Animals; D002317:Cardiovascular Agents / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy / Q000201:enzymology; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use; D006655:Histone Deacetylases / Q000378:metabolism*; D006801:Humans; D009206:Myocardium / Q000201:enzymology* / Q000473:pathology; D011499:Protein Processing, Post-Translational / Q000187:drug effects; D015398:Signal Transduction
chemical_list: D002317:Cardiovascular Agents; D056572:Histone Deacetylase Inhibitors; D006655:Histone Deacetylases